Biology subjects

Merico, D.

Publications and source records attributed to Merico, D..

12 recordsLinked to original sources

bioRxiv2026

Back to basics: Observed statistics are sufficient to predict drug responses

Predicting how cells, tissues, and patients will respond to a drug, cytokine, or genetic perturbation is central to biological and clinical reasoning. The practical goal is to estimate the analysis-ready readouts that support this reasoning: which cellular responses are context-dependent, which perturbations reveal shared or divergent mechanisms, and which observations should become the basis for the next experiment. Here we introduce Rhaister, a perturbation-response predictor that operates directly on screen-level summary statistics. By measuring just a few perturbations in a new biological context, Rhaister predicts the unmeasured perturbations by learning how response patterns vary across reference contexts. This formulation applies to both fine-grained molecular readouts, such as transcriptional responses from Tahoe-100M or other large perturbation screen, or on phenotypic endpoints. To train and apply Rhaister on pheno-typic endpoints we created Emerald Bay, a purpose-built Tahoe dataset that unifies multi-day cancer drug perturbation, pooled Mosaic tumor contexts, and paired transcriptomic response measurements*. Across these settings, Rhaister matches or exceeds substantially more expensive virtual-cell models, often achieving the highest values possible in evaluation metrics, while training in seconds and running predictions in milliseconds. On Emerald Bay, Rhaister predicts context-specific drug phenotypes from sensitivity measurements alone and improves further when including transcriptomic information. We also introduce Rhaister-O, predicting drug responses in new contexts from baseline expression alone and, to our knowledge, provides the first zero-shot model for this task. Rhaister establishes summary-statistic perturbation modeling as a fast, interpretable framework for predicting biological response across new contexts.

genomics↗

bioRxiv2026

ProteomeScan: A Toolkit For Target Validation By Proteome-Wide Docking And Analysis

The problem of identifying which protein target a potential drug-like molecule interacts with is crucial for both the study of existing drugs and the design of new therapeutic compounds. Despite the importance of target identification, existing computational approaches remain limited in terms of speed, accuracy, and protein target coverage. We introduce ProteomeScan, a large-scale, gene-driven computational toolkit for systematic proteome-wide scanning to uncover hidden or previously uncharacterized protein-ligand interactions. ProteomeScan leverages cloud-scale high performance computing to perform extensive molecular docking simulations across the human proteome to rank candidate targets based on binding affinities. After filtering promiscuous targets, we found that ProteomeScan ranks known target significantly better than a random baseline for a set of control compounds. Furthermore, we performed physical analyses of predicted binding modes for both promiscuous and known protein-ligand binding pairs to validate that ProteomeScan identifies interactions with valid binding pockets. In addition, we conducted experiments using mutant variants of proteins to study how mutations affect binding behavior. We have open sourced the core ProteomeScan algorithm as part of the DeepChem ecosystem to enhance transparency and reproducibility. Author summary

bioinformatics↗

bioRxiv2025

SigSpace: an LLM-based agent for drug responsesignature interpretation

Agent systems powered by large language models (LLMs) are increasingly applied in computational biology to automate analysis, integrate data, and accelerate discovery. Here, we investigate the capacity of LLM-driven agents to interpret transcriptional response signatures of drug perturbations in cancer cell lines, a task central to understanding drug mechanisms of action (MoAs) and supporting cancer drug discovery. Leveraging the Tahoe-100M dataset of 100 million transcriptomic profiles across 1,100 small-molecule perturbations and 50 cancer cell lines, we developed an LLM-based agent system, SigSpace, that processes differential gene expression signatures and generates concise, human-readable summaries of drug responses. We then tested whether blinded response signature summaries could be correctly matched to their corresponding drug identity or MoA. Our results show that LLM-generated summaries consistently outperform random baselines and that the choice of LLM model and signature score significantly influences performance. These findings highlight the potential of LLMs to enhance interpretation of complex transcriptional data to enable drug discovery. Future directions for improvement include exploring alternative response signature formats, improving summarization fidelity, benchmarking performance across different summary formats and lengths, and broadening applications to additional datasets and predictive tasks in drug discovery.

bioinformatics↗

bioRxiv2025

Tahoe-x1: Scaling Perturbation-Trained Single-CellFoundation Models to 3 Billion Parameters

Foundation models have transformed natural language processing and computer vision, yet their potential in single-cell biology--particularly for complex diseases such as cancer-- remains underexplored. We present Tahoe-x1 (Tx1), a family of perturbation-trained single-cell foundation models with up to 3 billion parameters. Tx1 is pretrained on large-scale single-cell transcriptomic datasets, including the Tahoe-100M perturbation compendium, and fine-tuned for cancer-relevant tasks. Through architectural optimizations, data loader refinements, and efficient training strategies, Tx1 achieves 3-30x higher compute efficiency than prior implementations of cell-state models. Tx1 jointly learns representations of genes, cells, and compounds using a masked-expression generative objective that incorporates a drug token, enabling flexible adaptation to diverse downstream applications. We evaluate Tx1 across four key disease-relevant benchmarks: (1) prediction of overall and context-specific gene essentiality, (2) identification of genes contributing to the hallmarks of cancer, (3) cell-type classification, and (4) prediction of perturbation responses in held-out cellular contexts. Tx1 achieves state-of-the-art performance across all tasks. We release pretrained checkpoints, training code, and evaluation workflows to accelerate the development of perturbation-trained single-cell foundation models for applications in precision oncology and beyond. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=52 SRC="FIGDIR/small/683759v1_ufig1.gif" ALT="Figure 1"> View larger version (13K): org.highwire.dtl.DTLVardef@aa33d5org.highwire.dtl.DTLVardef@310a38org.highwire.dtl.DTLVardef@195f204org.highwire.dtl.DTLVardef@143f7e3_HPS_FORMAT_FIGEXP M_FIG C_FIG

systems biology↗

bioRxiv2025

Tahoe-100M: A Giga-Scale Single-Cell Perturbation Atlas for Context-Dependent Gene Function and Cellular Modeling

Building predictive models of the cell requires systematically mapping how perturbations reshape each cells state, function, and behavior. Here, we present Tahoe-100M, a giga-scale single-cell atlas of 100 million transcriptomic profiles measuring how each of 1,100 small-molecule perturbations impact cells across 50 cancer cell lines. Our high-throughput Mosaic platform, composed of a highly diverse and optimally balanced "cell village", reduces batch effects and enables parallel profiling of thousands of conditions at single-cell resolution at an unprecedented scale. As the largest single-cell dataset to date, Tahoe-100M enables artificial-intelligence (AI)-driven models to learn context-dependent functions, capturing fundamental principles of gene regulation and network dynamics. Although we leverage cancer models and pharmacological compounds to create this resource, Tahoe-100M is fundamentally designed as a broadly applicable perturbation atlas and supports deeper insights into cell biology across multiple tissues and contexts. By publicly releasing this atlas, we aim to accelerate the creation and development of robust AI frameworks for systems biology, ultimately improving our ability to predict and manipulate cellular behaviors across a wide range of applications.

genomics↗

bioRxiv2020

Transcriptome-Wide Off-Target Effects of Steric-Blocking Oligonucleotides

Steric-blocking oligonucleotides (SBOs) are short, single-stranded nucleic acids designed to modulate gene expression by binding to mRNA and blocking access from cellular machinery such as splicing factors. SBOs have the potential to bind to near-complementary sites in the transcriptome, causing off-target effects. In this study, we used RNA-seq to evaluate the off-target differential splicing events of 81 SBOs and differential expression events of 46 SBOs. Our results suggest that differential splicing events are predominantly hybridization-driven, while differential expression events are more common and driven by other mechanisms. We further evaluated the performance of in silico screens for off-target events, and found an edit distance cutoff of three to result in a sensitivity of 14% and false discovery rate of 99%. A machine learning model incorporating splicing predictions substantially improved the ability to prioritize low edit distance hits, increasing sensitivity from 4% to 26% at a fixed FDR. Despite these large improvements in performance, the approach does not detect the majority of events at a false discovery rate below 99%. Our results suggest that in silico methods are currently of limited use for predicting the off-target effects of SBOs.

molecular biology↗

bioRxiv2020

Genes and pathways implicated in tetralogy of Fallot revealed by ultra-rare variant burden analysis in 231 genome sequences

Recent genome-wide studies of rare genetic variants have begun to implicate novel mechanisms for tetralogy of Fallot (TOF), a severe congenital heart defect (CHD). To provide statistical support for case-only data without parental genomes, we re-analyzed genome sequences of 231 individuals with TOF or related CHD. We adapted a burden test originally developed for de novo variants to assess singleton variant burden in individual genes, and in gene-sets corresponding to functional pathways and mouse phenotypes, accounting for highly correlated gene-sets, and for multiple testing. The gene burden test identified a significant burden of deleterious missense variants in NOTCH1 (Bonferroni-corrected p-value <0.01). These NOTCH1 variants showed significant enrichment for those affecting the extracellular domain, and especially for disruption of cysteine residues forming disulfide bonds (OR 39.8 vs gnomAD). Individuals with NOTCH1 variants, all with TOF, were enriched for positive family history of CHD. Other genes not previously implicated in TOF had more modest statistical support and singleton missense variant results were non-significant for gene-set burden. For singleton truncating variants, the gene burden test confirmed significant burden in FLT4. Gene-set burden tests identified a cluster of pathways corresponding to VEGF signaling (FDR=0%), and of mouse phenotypes corresponding to abnormal vasculature (FDR=0.8%), that suggested additional candidate genes not previously identified (e.g., WNT5A and ZFAND5). Analyses using unrelated sequencing datasets supported specificity of the findings for CHD. The findings support the importance of ultra-rare variants disrupting genes involved in VEGF and NOTCH signaling in the genetic architecture of TOF. These proof-of-principle data indicate that this statistical methodology could assist in analyzing case-only sequencing data in which ultra-rare variants, whether de novo or inherited, contribute to the genetic etiopathogenesis of a complex disorder. Author summaryWe analyzed the ultra-rare nonsynonymous variant burden for genome sequencing data from 231 individuals with congenital heart defects, most with tetralogy of Fallot. We adapted a burden test originally developed for de novo variants. In line with other studies, we identified a significant truncating variant burden for FLT4 and deleterious missense burden for NOTCH1, both passing a stringent Bonferroni multiple-test correction. For NOTCH1, we observed frequent disruption of cysteine residues establishing disulfide bonds in the extracellular domain. We also identified genes with BH-FDR <10% that were not previously implicated. To overcome limited power for individual genes, we tested gene-sets corresponding to functional pathways and mouse phenotypes. Gene-set burden of truncating variants was significant for vascular endothelial growth factor signaling and abnormal vasculature phenotypes. These results confirmed previous findings and suggested additional candidate genes for experimental validation in future studies. This methodology can be extended to other case-only sequencing data in which ultra-rare variants make a substantial contribution to genetic etiology.

genomics↗

bioRxiv2019

ATP7B Variant c.1934T>G p.Met645Arg Causes Wilson Disease by Promoting Exon 6 Skipping

Wilson Disease is a recessive genetic disorder caused by pathogenic loss-of-function variants in the ATP7B gene. It is characterized by disrupted copper homeostasis resulting in liver disease and/or neurological abnormalities. The variant NM_000053.3:c.1934T>G (Met645Arg) has been reported as compound heterozygous and is highly prevalent among Wilson Disease patients of Spanish descent. Accordingly, it is classified as pathogenic by leading molecular diagnostic centers. However, functional studies suggest that the amino acid change does not alter protein function, leading one ClinVar submitter to question its pathogenicity. Here we used a minigene system and gene-edited HepG2 cells to demonstrate that c.1934T>G causes approximately 70% skipping of exon 6. Exon 6 skipping results in frameshift and stop gain, which is expected to cause loss of ATP7B function. The elucidation of the mechanistic effect for this variant resolves any doubt about its pathogenicity and enables the development of genetic medicines for restoring correct splicing.

genetics↗

bioRxiv2018

Complete Disruption of Autism-Susceptibility Genes by Gene-Editing Predominantly Reduces Functional Connectivity of Isogenic Human Neurons

Autism Spectrum Disorder is phenotypically and genetically heterogeneous, but genomic analyses have identified candidate susceptibility genes. We present a CRISPR gene editing strategy to insert a protein tag and premature termination sites creating an induced pluripotent stem cell (iPSC) knockout resource for functional studies of 10 ASD-relevant genes (AFF2/FMR2, ANOS1, ASTN2, ATRX, CACNA1C, CHD8, DLGAP2, KCNQ2, SCN2A, TENM1). Neurogenin 2 (NEUROG2)-directed differentiation of iPSCs allowed production of cortical excitatory neurons, and mutant proteins were not detectable. RNAseq revealed convergence of several neuronal networks. Using both patch-clamp and multi-electrode array approaches, the electrophysiological deficits measured were distinct for different mutations. However, they culminated in a consistent reduction in synaptic activity, including reduced spontaneous excitatory post-synaptic current frequencies in AFF2/FMR2-, ASTN2-, ATRX-, KCNQ2- and SCN2A-null neurons. Despite ASD susceptibility genes belonging to different gene ontologies, isogenic stem cell resources can reveal common functional phenotypes, such as reduced functional connectivity.

neuroscience↗

bioRxiv2018

Matching drug transcriptional signatures to rare losses disrupting synaptic gene networks identifies known and novel candidate drugs for schizophrenia

Schizophrenia is a complex neuropsychiatric disorder. The etiology is not fully understood, but genetics plays an important role. Pathway analysis of genetic variants have suggested a central role for neuronal synaptic processes. Currently available antipsychotic medications successfully control positive symptoms (hallucinations and delusions) largely by inhibiting the dopamine D2 receptors; however, these drugs have more limited impact on negative symptoms (social withdrawal, flat affections, anhedonia) and cognitive deterioration. Drug development efforts have focused on a wide range of neurotransmitter systems and other agents, with conflicting or inconclusive results. New drug development paradigms are needed. A recent analysis, using common variant association results to match drugs based on their transcriptional perturbation signature, found drugs enriched in known antipsychotics plus novel candidates.\n\nWe followed a similar approach, but started our analysis from a synaptic gene network implicated by rare copy number loss variants. We found that a significant number of antipsychotics (p-value = 0.0002) and other psychoactive drugs (p-value = 0.0004) upregulate synaptic network genes. Based on global gene expression similarity, active drugs formed two main clusters: one with many known antipsychotics and antidepressants, the other with various drug categories including two nootropics. We specifically recommend further examination of nootropics with limited side effects (meclofenoxate, piracetam and vinpocetine) for combination therapy with antipsychotics to improve cognitive performance. Detailed experimental follow-up is required to further evaluate other candidate drugs lacking an official nervous system indication, although, for at least a few of these, psychoactive effects have been reported in the literature.

bioinformatics↗

bioRxiv2018

Allele-specific transcription factor binding as a benchmark for assessing variant impact predictors

Genetic variation has long been known to alter transcription factor binding sites, resulting in sometimes major phenotypic consequences. While the performance for current binding site predictors is well characterised, little is known on how these models perform at predicting impact of variants. We collected and curated over 132,000 potential allele-specific binding (ASB) ChIP-seq variants across 101 transcription factors (TFs). We then assessed the accuracy of TF binding models from five different methods on these high-confidence measurements, finding that deep learning methods were best performing yet still have room for improvement. Importantly, machine learning methods were consistently better than the venerable position weight matrix (PWM). Finally, predictions for certain TFs were consistently poor, and our investigation supports efforts to use features beyond sequence, such as methylation, DNA shape, and post-translational modifications. We submit that ASB data is a valuable benchmark for variant impact on TF binding.

bioinformatics↗

bioRxiv2017

Pathway enrichment analysis of -omics data

Pathway enrichment analysis helps gain mechanistic insight into large gene lists typically resulting from genome scale (-omics) experiments. It identifies biological pathways that are enriched in the gene list more than expected by chance. We explain pathway enrichment analysis and present a practical step-by-step guide to help interpret gene lists resulting from RNA-seq and genome sequencing experiments. The protocol comprises three major steps: define a gene list from genome scale data, determine statistically enriched pathways, and visualize and interpret the results. We focus on differentially expressed genes and mutated cancer genes, however the described principles can be applied to diverse -omics data. The protocol is designed for biologists with no prior bioinformatics training and uses freely available software including g:Profiler, GSEA, Cytoscape and Enrichment Map.

bioinformatics↗